Chordate Medical Holding Yönetim

Yönetim kriter kontrolleri 3/4

Chordate Medical Holding CEO'su Anders Weilandt, Jun2017 tarihinde atandı, in görev süresi 7.42 yıldır. şirketin hisselerinin 0.82% doğrudan sahiptir ve bu hisselerin değeri SEK 163.30K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 7.9 yıl ve 7.6 yıldır.

Anahtar bilgiler

Anders Weilandt

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	7.4yrs
CEO sahipliği	0.8%
Yönetim ortalama görev süresi	7.9yrs
Yönetim Kurulu ortalama görev süresi	7.6yrs

Son yönetim güncellemeleri

Recent updates

We Think Chordate Medical Holding (NGM:CMH) Needs To Drive Business Growth Carefully

May 20

CEO

Anders Weilandt (63 yo)

7.4yrs

Görev süresi

Mr. Anders Weilandt served as Director at Neola Medical AB (formerly known as GPX Medical AB (publ)) since May 2022 until 2024. Mr. Weilandt serves as the Chief Executive Officer at Chordate Medical Holdin...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Anders Weilandt	CEO & MD	7.4yrs	Veri yok	0.82% SEK 163.3k
Niklas Lindecrantz	Chief Financial Officer	7.1yrs	Veri yok	0.036% SEK 7.2k
Jan Lindberg	CTO and Head of R&D	12.8yrs	Veri yok	0.010% SEK 2.0k
Jan Hermansson	Chief Scientific Officer and Clinical Research & Medical Director	no data	Veri yok	0.31% SEK 61.2k
Helena Thedius	Sales & Marketing Manager	8.4yrs	Veri yok	Veri yok

7.9yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim: CMH 'un yönetim ekibi deneyimli ve deneyimlidir ( 7.9 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Tommy Hedberg	Independent Director	10.4yrs	SEK 100.00k	2.54% SEK 506.9k
Gunilla Lundmark	Independent Director	7.6yrs	SEK 100.00k	Veri yok
Henrik Rammer	Independent Chairman	10yrs	SEK 180.00k	1.36% SEK 271.9k
Caroline Brandberg	Independent Director	3.1yrs	SEK 100.00k	3.89% SEK 777.0k
Otto Skolling	Vice Chairman	1.5yrs	SEK 140.00k	Veri yok

7.6yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CMH 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.6 yıldır).

Chordate Medical Holding Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

CEO & MD recently bought kr52k worth of stock

Otto Skolling Elected to Chordate Medical's Board

Chordate Medical Holding AB (publ) Appoints Otto Skolling as New Vice Chairman of the Board of Directors

No independent directors

Recent updates

Third quarter 2024 earnings released

Chordate Medical Receives Market Authorization for the Migraine Indication in Saudi Arabia

Chordate Medical Holding AB (publ) to Report Q1, 2025 Results on May 23, 2025

Chordate Medical Holding AB (publ) Reports Conclusions from First Data Monitoring of the Ongoing Long Term Open Study on Chronic Migraine: PM010

Second quarter 2024 earnings released

Chordate Medical Holding AB (publ) to Report Fiscal Year 2024 Final Results on Apr 11, 2025

First quarter 2024 earnings released

Chordate Medical Receives Patent Approval in the US

CEO & MD recently bought kr52k worth of stock

Full year 2023 earnings released: kr0.13 loss per share (vs kr0.18 loss in FY 2022)

New major risk - Shareholder dilution

Chordate Medical Holding AB (Publ) Announces the European Patent Office Grants New Patent

Chordate Medical Completes Training of Clinic Staff and Assists in Initiation of Treatment for First Three Patients at the Private Clinic in Hamburg

Chordate Medical Holding AB (Publ) Receives First Installation of the Ozilia Migraine Treatment at a Private Clinic in Hamburg

New major risk - Revenue and earnings growth

Chordate Medical Holding AB (publ) to Report Fiscal Year 2023 Final Results on Apr 12, 2024

Chordate Medical Holding AB (publ) to Report Q3, 2023 Results on Nov 01, 2023

Chordate Medical Holding AB (publ) Introduces New Trademark for Migraine Treatment: Ozilia™ - Migraine Relief

New major risk - Financial position

Chordate Medical Holding AB (publ) to Report Q2, 2023 Results on Aug 31, 2023

Chordate Medical Holding AB (publ) Announces Complete Study Results from Migraine Study Submitted to Scientific Journal

Otto Skolling Elected to Chordate Medical's Board

Chordate Medical Holding AB (publ) to Report Q1, 2023 Results on May 25, 2023

Chordate Medical Holding AB (publ) Appoints Otto Skolling as New Vice Chairman of the Board of Directors

NHS Gives Ethical Approval for Chordate's New Migraine Study

Full year 2022 earnings released: kr0.18 loss per share (vs kr0.19 loss in FY 2021)

Chordate Introduces Migraine Treatment in Finland

Chordate Medical Launches Market Introduction of Migraine Treatment in Finland

Chordate Medical Holding AB (publ) Announces Subgroup Analysis of A Randomised Controlled Clinical Trial

Chordate Medical Holding AB (Publ) Launches Market Introduction of Migraine Treatment in Germany

First quarter 2022 earnings released

Chordate Medical Holding AB (Publ) Updates on Ongoing and Planned Clinical Studies

No independent directors

Chordate Medical Holding AB (publ) Completes First Phase in the US

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Chordate Medical Holding AB (publ) to Report Q3, 2022 Results on Nov 18, 2022

Chordate Medical Holding AB (publ) to Report Fiscal Year 2021 Results on Feb 25, 2022

Third quarter 2021 earnings released: kr0.03 loss per share (vs kr0.09 loss in 3Q 2020)

Second quarter 2021 earnings released

First quarter 2021 earnings released

We Think Chordate Medical Holding (NGM:CMH) Needs To Drive Business Growth Carefully

Full year 2020 earnings released: kr0.41 loss per share (vs kr0.98 loss in FY 2019)

New 90-day high: kr0.60

Chordate Medical Notifies on When to Resume Migraine Study

New 90-day low: kr0.39

New 90-day low: kr0.45

New 90-day low: kr0.92

New 90-day high - kr1.96

New 90-day high - kr1.15

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş